BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Specenier P, Vermorken JB. Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol 2012;2012:163752. [PMID: 22745915 DOI: 10.5402/2012/163752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Cannonier SA, Gonzales CB, Ely K, Guelcher SA, Sterling JA. Hedgehog and TGFβ signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. Oncotarget 2016;7:76062-75. [PMID: 27738315 DOI: 10.18632/oncotarget.12584] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
2 Pickhard A, Piontek G, Seidl C, Kopping S, Blechert B, Mißlbeck M, Brockhoff G, Bruchertseifer F, Morgenstern A, Essler M. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. Nucl Med Biol 2014;41:68-76. [PMID: 24210808 DOI: 10.1016/j.nucmedbio.2013.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
3 Masuda M, Toh S, Wakasaki T, Suzui M, Joe AK. Somatic evolution of head and neck cancer - biological robustness and latent vulnerability. Mol Oncol 2013;7:14-28. [PMID: 23168041 DOI: 10.1016/j.molonc.2012.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Kostakoglu L, Fardanesh R, Posner M, Som P, Rao S, Park E, Doucette J, Stein EG, Gupta V, Misiukiewicz K, Genden E. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist 2013;18:1108-17. [PMID: 24037978 DOI: 10.1634/theoncologist.2013-0068] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
5 Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013;7:77-90. [PMID: 23723688 DOI: 10.2147/BTT.S43628] [Cited by in Crossref: 11] [Cited by in F6Publishing: 38] [Article Influence: 1.2] [Reference Citation Analysis]
6 Bossi P, Platini F. Radiotherapy plus EGFR inhibitors: synergistic modalities. Cancers Head Neck 2017;2:2. [PMID: 31093349 DOI: 10.1186/s41199-016-0020-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Longton E, Schmit K, Fransolet M, Clement F, Michiels C. Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. Front Oncol 2018;8:432. [PMID: 30345256 DOI: 10.3389/fonc.2018.00432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Zhang HJ, Yuan GL, Liang QL, Peng XX, Cheng SA, Jiang L. Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma. Oncol Lett 2018;15:7799-805. [PMID: 29740494 DOI: 10.3892/ol.2018.8284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]